Tertiary lymphoid structures in epithelioid malignant peritoneal mesothelioma are associated with neoadjuvant chemotherapy, but not with prognosis.
Adult
Aged
Aged, 80 and over
Female
France
/ epidemiology
Humans
Lung Neoplasms
/ pathology
Lymph Nodes
/ pathology
Male
Mesothelioma
/ pathology
Mesothelioma, Malignant
/ metabolism
Middle Aged
Neoadjuvant Therapy
/ methods
Peritoneal Neoplasms
/ metabolism
Peritoneum
/ pathology
Prognosis
Retrospective Studies
Tertiary Lymphoid Structures
/ pathology
Tumor Microenvironment
Biomarker
Malignant epithelioid peritoneal mesothelioma
Mesothelioma
Tertiary lymphoid structures
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
13
11
2020
accepted:
05
04
2021
revised:
15
03
2021
pubmed:
16
4
2021
medline:
29
10
2021
entrez:
15
4
2021
Statut:
ppublish
Résumé
Epithelioid mesothelioma is the most prevalent subtype of diffuse malignant peritoneal mesothelioma. The relationship between a strong adaptive immune response and a better prognosis in malignant solid tumors is widely known. Due to the low incidence of epithelioid malignant peritoneal mesothelioma (EMPM), very little is known about their immune micro-environment. We encountered several cases of tertiary lymphoid structures in EMPM in a previous study and aimed to investigate in the same series the prevalence, clinicopathological features, and the prognostic impact associated with tertiary lymphoid structures in EMPM (TLS-EMPM). Cases of EMPM, from 1995 to 2018, were retrieved from 7 French institutions from the RENAPE Network. The predictions in terms of overall survival (OS) and progression-free survival (PFS) of TLS-EMPM were analyzed. We report 52 cases of TLS-EMPM among a series of 138 cases of EMPM. TLS-EMPM was significantly associated with neoadjuvant chemotherapy, and was not a prognostic indicator for OS (p = 0.652) and PFS (p = 0.804) in our series. TLS is a component of the host immune response to EMPM significantly associated with neoadjuvant chemotherapy, but was not a predictor of prognosis for overall and progression-free survivals in this series. These findings provide another possible etiology for tertiary lymphoid structures.
Identifiants
pubmed: 33855595
doi: 10.1007/s00428-021-03099-1
pii: 10.1007/s00428-021-03099-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
765-772Investigateurs
Julio Abba
(J)
Karine Abboud
(K)
Mohammad Alyami
(M)
Amroun Koceila
(A)
Catherine Arvieux
(C)
Naoual Bakrin
(N)
Sandrine Barbois
(S)
Houda Ben Rejeb
(HB)
Jean-Marc Bereder
(JM)
Isabelle Bonnefoy
(I)
Pierre-Emmanuel Bonnot
(PE)
Olivier Bouche
(O)
Dominique Bouzard
(D)
Cécile Brigand
(C)
Sébastien Carrère
(S)
Bertrand Célérier
(B)
Cécilia Ceribelli
(C)
Julien Coget
(J)
Thomas Courvoisier
(T)
Cécile de Chaisemartin
(C)
Jean-Baptiste Delhorme
(JB)
Anthony Dohan
(A)
Frédéric Dumont
(F)
Sylvaine Durand-Fontanier
(S)
Clarisse Eveno
(C)
Gwenaël Ferron
(G)
Johan Gagniere
(J)
Alexandre Galan
(A)
Laurent Ghouti
(L)
François-Noël Gilly
(FN)
Laurence Gladieff
(L)
Diane Goéré
(D)
Jean-Marc Guilloit
(JM)
Frédéric Guyon
(F)
Bruno Heyd
(B)
Christine Hoeffel
(C)
Charles Honoré
(C)
Eve Huart
(E)
Martin Hübner
(M)
Rachid Kaci
(R)
Reza Kianmanesh
(R)
Jérémie Lefevre
(J)
Bernard Lelong
(B)
Justine Lerooy
(J)
Agnès Leroux-Broussier
(A)
Réa Lo Dico
(RL)
Frédéric Marchal
(F)
Pascale Mariani
(P)
Pierre Meeus
(P)
Cédric Nadeau
(C)
Cécile Odin
(C)
Pablo Ortega-Deballon
(P)
Brice Paquette
(B)
Guillaume Passot
(G)
Patrice Peyrat
(P)
Denis Pezet
(D)
Guillaume Piessen
(G)
Nicolas Pirro
(N)
Hélène Plouhinec
(H)
Marc Pocard
(M)
Flora Poizat
(F)
François Quenet
(F)
Patrick Rat
(P)
Pierre Rousselot
(P)
Pascal Rousset
(P)
Hélène Senellart
(H)
Olivia Sgarbura
(O)
Igor Sielezneff
(I)
Isabelle Sourrouille
(I)
Magali Svrcek
(M)
Abdelkader Taibi
(A)
Emilie Thibaudeau
(E)
Yann Touchefeu
(Y)
Jean-Jacques Tuech
(JJ)
Sharmini Varatharajah
(S)
Delphine Vaudoyer
(D)
Sophie Vermersch
(S)
Véronique Verriele-Beurrier
(V)
Romuald Wernert
(R)
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Glehen O. Mésothéliome péritonéal malin. In: Orphanet. https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=168811&lng=FR
Husain A, Colby T, Ordóñez N et al (2018) Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 142:89–108. https://doi.org/10.5858/arpa.2017-0124-RA
doi: 10.5858/arpa.2017-0124-RA
pubmed: 28686500
Yan T, Deraco M, Baratti D et al (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27:6237–6242. https://doi.org/10.1200/JCO.2009.23.9640
doi: 10.1200/JCO.2009.23.9640
pubmed: 19917862
Fridman W, Pagès F, Sautès-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12:298–306. https://doi.org/10.1038/nrc3245
doi: 10.1038/nrc3245
pubmed: 22419253
Maoz A, Dennis M, Greenson J (2019) The Crohn’s-like lymphoid reaction to colorectal cancer-tertiary lymphoid structures with immunologic and potentially therapeutic relevance in colorectal cancer. Front Immunol 10:1884. https://doi.org/10.3389/fimmu.2019.01884
doi: 10.3389/fimmu.2019.01884
pubmed: 31507584
pmcid: 6714555
Väyrynen J, Sajanti S, Klintrup K et al (2014) Characteristics and significance of colorectal cancer associated lymphoid reaction. Int J Cancer 134:2126–2135. https://doi.org/10.1002/ijc.28533
doi: 10.1002/ijc.28533
pubmed: 24154855
Villeneuve L, Passot G, Glehen O et al (2017) The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry. Orphanet J Rare Dis 12:37. https://doi.org/10.1186/s13023-017-0571-y
doi: 10.1186/s13023-017-0571-y
pubmed: 28212684
pmcid: 5316145
Jacquet P, Sugarbaker P (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359–374. https://doi.org/10.1007/978-1-4613-1247-5_23
doi: 10.1007/978-1-4613-1247-5_23
pubmed: 8849962
Graham D, Appelman H (1990) Crohn’s-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator. Mod Pathol 3:332–335
pubmed: 2362940
Ueno H, Hashiguchi Y, Shimazaki H et al (2013) Objective criteria for crohn-like lymphoid reaction in colorectal cancer. Am J Clin Pathol 139:434–441. https://doi.org/10.1309/AJCPWHUEFTGBWKE4
doi: 10.1309/AJCPWHUEFTGBWKE4
pubmed: 23525613
Villeneuve L, Isaac S, Glehen O et al (2014) The RENAPE Network: towards a new healthcare organization for the treatment of rare tumors of the peritoneum. Description of the Network and Role of the Pathologists. Ann Pathol 34:4–8. https://doi.org/10.1016/j.annpat.2014.01.008
doi: 10.1016/j.annpat.2014.01.008
pubmed: 24630631
Rosen L, Karrison T, Ananthanarayanan V et al (2018) Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. Mod Pathol 31:598–606. https://doi.org/10.1038/modpathol.2017.170
doi: 10.1038/modpathol.2017.170
pubmed: 29327706
Kadota K, Suzuki K, Colovos C et al (2012) A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma. Mod Pathol 25:260–271. https://doi.org/10.1038/modpathol.2011.146
doi: 10.1038/modpathol.2011.146
pubmed: 21983936
Nicholson A, Sauter J, Nowak A et al (2020) EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach. J Thorac Oncol 29:29–49. https://doi.org/10.1016/j.jtho.2019.08.2506
doi: 10.1016/j.jtho.2019.08.2506
R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2013; Available from: http://www.r-project.org/
Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48:452–458. https://doi.org/10.1038/bmt.2012.244
doi: 10.1038/bmt.2012.244
pubmed: 23208313
pmcid: 23208313
Baker P, Clement P, Young R (2005) Malignant peritoneal mesothelioma in women: a study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. Am J Clin Pathol 123:724–737. https://doi.org/10.1309/2h0n-vrer-pp2l-jdua
doi: 10.1309/2h0n-vrer-pp2l-jdua
pubmed: 15981812
Rivera E, Coffey J, Walsh D, Ehrenpreis E (2019) The mesentery, systemic inflammation, and Crohn’s disease. Inflamm Bowel Dis 25:226–234. https://doi.org/10.1093/ibd/izy201
doi: 10.1093/ibd/izy201
pubmed: 29920595
Butnor K, Pavlisko E, Sporn T, Roggli V (2017) Malignant peritoneal mesothelioma and Crohn disease. J Clin Pathol 70:228–232. https://doi.org/10.1136/jclinpath-2016-203945
doi: 10.1136/jclinpath-2016-203945
pubmed: 27484913
Hato S, Khong A, de Vries I, Lesterhuis W (2014) Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res 20:2831–2037. https://doi.org/10.1158/1078-0432
doi: 10.1158/1078-0432
pubmed: 24879823
Deraco M, Baratti D, Hutanu I et al (2013) The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 20:1093–1100. https://doi.org/10.1245/s10434-012-2845-x
doi: 10.1245/s10434-012-2845-x
pubmed: 23456386
Kepenekian V, Elias D, Passot G et al (2016) Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study. Eur J Cancer 65:69–79. https://doi.org/10.1016/j.ejca.2016.06.002
doi: 10.1016/j.ejca.2016.06.002
pubmed: 27472649
Chu G, van Zandwijk N, Rasko J (2019) The immune microenvironment in mesothelioma: mechanisms of resistance to immunotherapy. Front Oncol 9:1366. https://doi.org/10.3389/fonc.2019.01366
doi: 10.3389/fonc.2019.01366
pubmed: 31867277
pmcid: 6908501
Fuchs T, Chou A, Sioson L et al (2020) Stromal tumour-infiltrating lymphocytes (TILs) assessed using the ITWG system do not predict overall survival in a cohort of 337 cases of mesothelioma. Histopathology 76:1095–1101. https://doi.org/10.1111/his.14106
doi: 10.1111/his.14106
pubmed: 32215942
Vanbervliet-Defrance B, Delaunay T, Daunizeau T et al (2020) Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma. Cancer Lett 472:29–39. https://doi.org/10.1016/j.canlet.2019.12.016
doi: 10.1016/j.canlet.2019.12.016
pubmed: 31838086